- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00248963
Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception
May 17, 2006 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 Mg and Ethinyl Estradiol 20 Mg in a Continuous 28-Day Regimen for Oral Contraception Versus a Cyclic 21-Day Regimen Oral Contraceptive
To evaluate the contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen and to evaluate the safety compared to LNG 100 mg/EE 20 mg for 21 days followed by a 7-day hormone-free interval in a cyclic regimen.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
600
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy women aged 18 to 49 years who are willing to rely upon a combination birth control pill as their only method of contraception.
- Women must be sexually active and at risk for becoming pregnant.
- Women must have had regular (21- to 35- day) menstrual cycles for the 3-month period preceding study visit 1.
Exclusion Criteria:
- High blood pressure
- Age greater then 34 and smoking more than 15 cigarettes per day.
- Depression requiring hospitalization or associated with suicidal ideation within the last 3 years.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Educational/Counseling/Training
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To evaluate the contraceptive efficacy of an OC containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen and the safety compared to LNG 100 mg/EE 20 mg for 21 days followed by a 7-day hormone-free interval in a cyclic regimen
|
Secondary Outcome Measures
Outcome Measure |
---|
To evaluate the effects on vaginal bleeding profile, hemostatic balance, lipid, carbohydrate, bone metabolism measures, hemoglobin levels, discontinuation rates, compliance with respect to pill taking, subject satisfaction
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Completion
October 1, 2004
Study Registration Dates
First Submitted
November 2, 2005
First Submitted That Met QC Criteria
November 2, 2005
First Posted (Estimate)
November 4, 2005
Study Record Updates
Last Update Posted (Estimate)
May 19, 2006
Last Update Submitted That Met QC Criteria
May 17, 2006
Last Verified
May 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Levonorgestrel
- Estradiol
- Ethinyl Estradiol
Other Study ID Numbers
- 0858A2-315
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Contraceptive
-
BayerCompletedOral ContraceptiveSwitzerland, Portugal, Chile, Italy, Korea, Republic of, Venezuela, Philippines, Colombia, Thailand, Argentina, Germany, Russian Federation, United Kingdom, Czech Republic
-
BayerCompletedOral ContraceptiveGermany
-
University of Southern CaliforniaUnited States Department of DefenseCompleted
-
Regenex Pharmaceutical, ChinaUnknownOral ContraceptiveChina
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedOral Contraceptive | HemostasisGermany, Israel, Italy, Spain
-
Teva Women's HealthCompletedOral Contraceptive | HemostasisUnited States, Italy
-
Planned Parenthood League of MassachusettsCompletedOral Contraceptive Pill AdherenceUnited States
-
University of AarhusRecruitingRecovery | Oral Contraceptive UseDenmark
-
EZUS-LYON 1Laboratoire Interuniversitaire de Biologie de la MotricitéRecruitingMenstrual Cycle | Oral Contraceptive UseFrance
Clinical Trials on Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Laboratorios Andromaco S.A.Completed
-
Laboratorios Andromaco S.A.Completed
-
Laboratorios Andromaco S.A.CompletedTherapeutic EquivalencyIndia
-
University of SaskatchewanCanadian Institutes of Health Research (CIHR)Completed
-
Regenex Pharmaceutical, ChinaUnknownOral ContraceptiveChina
-
University of CagliariUnknown
-
PfizerBoston Collaborative Drug Surveillance ProgramCompletedVenous Thrombosis | Pulmonary Embolism | Sinus Thrombosis, Intracranial
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Laboratorios Andromaco S.A.Completed